The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment

Overview

Journal New Dir Child Adolesc Dev

Specialty Pediatrics

Date 2020 Jul 14

PMID 32657046

Authors

Mei Tan

Megan Bowers

Phil Thuma

Elena L Grigorenko

Affiliations

Soon will be listed here.

Abstract

Efavirenz (EFV) is a well-known, effective anti-retroviral drug long used in first-line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 μg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its genetic underpinnings have been carried out, primarily with adult samples. A number of studies, however, have examined the genetic influences on the metabolism of EFV in children. Their primary goal has been to shed light on issues of appropriate pediatric dosing, as well as the manifestation of neurotoxic effects of EFV in some children. Although EFV is currently being phased out of use for the treatment of both adults and children, we share this line of research to highlight an important aspect of medical treatment that is relevant to understanding the development of children diagnosed with HIV.

References

Lindfelt T, OBrien J, Song J, Patel R, Winslow D . Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. Ann Pharmacother. 2010; 44(10):1572-8. DOI: 10.1345/aph.1P141. View

Salem A, Fletcher C, Brundage R . Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrob Agents Chemother. 2013; 58(1):136-43. PMC: 3910794. DOI: 10.1128/AAC.01738-13. View

. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013; 381(9875):1391-1403. PMC: 3641608. DOI: 10.1016/S0140-6736(12)62198-9. View

Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K . Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007; 8(6):547-58. DOI: 10.2217/14622416.8.6.547. View

Ter Heine R, Scherpbier H, Crommentuyn K, Bekker V, Beijnen J, Kuijpers T . A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther. 2008; 13(6):779-87. View

Xu B, Guo L, Lee S, Dong Q, Tan Y, Yao H . Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World J Gastroenterol. 2007; 13(14):2100-3. PMC: 4319132. DOI: 10.3748/wjg.v13.i14.2100. View

Mutwa P, Fillekes Q, Malgaz M, Tuyishimire D, Kraats R, Boer K . Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms. J Acquir Immune Defic Syndr. 2012; 60(4):400-4. DOI: 10.1097/QAI.0b013e3182569f57. View

Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A . Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003; 17(12):1741-51. DOI: 10.1097/00002030-200308150-00003. View

Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey T, Sirisanthana V . Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Antivir Ther. 2009; 14(3):315-20. View

10.

Viljoen M, Karlsson M, Meyers T, Gous H, Dandara C, Rheeders M . Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2011; 68(4):339-47. DOI: 10.1007/s00228-011-1148-7. View

11.

Waalewijn H, Turkova A, Rakhmanina N, Cressey T, Penazzato M, Colbers A . Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. Ther Drug Monit. 2019; 41(4):431-443. PMC: 6636807. DOI: 10.1097/FTD.0000000000000637. View

12.

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer N . Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008; 61(4):914-8. PMC: 3596857. DOI: 10.1093/jac/dkn029. View

13.

Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C . The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. Br J Clin Pharmacol. 2016; 82(1):185-98. PMC: 4917805. DOI: 10.1111/bcp.12934. View

14.

Rakhmanina N, van den Anker J . Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol. 2009; 6(1):95-103. PMC: 2810555. DOI: 10.1517/17425250903483207. View

15.

Marzolini C, Telenti A, Decosterd L, Greub G, Biollaz J, Buclin T . Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001; 15(1):71-5. DOI: 10.1097/00002030-200101050-00011. View

16.

Siccardi M, Olagunju A, Simiele M, DAvolio A, Calcagno A, Di Perri G . Class-specific relative genetic contribution for key antiretroviral drugs. J Antimicrob Chemother. 2015; 70(11):3074-9. DOI: 10.1093/jac/dkv207. View

17.

Apostolova N, Blas-Garcia A, Galindo M, Esplugues J . Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects. Eur J Pharmacol. 2017; 812:163-173. DOI: 10.1016/j.ejphar.2017.07.016. View

18.

Soeria-Atmadja S, Osterberg E, Gustafsson L, Dahl M, Eriksen J, Rubin J . Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PLoS One. 2017; 12(9):e0181316. PMC: 5590735. DOI: 10.1371/journal.pone.0181316. View

19.

Liu X, Ma Q, Zhao Y, Mu W, Sun X, Cheng Y . Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Pharmacotherapy. 2017; 37(9):1073-1080. PMC: 5600689. DOI: 10.1002/phar.1988. View

20.

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel K, Suda A . Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther. 2010; 88(5):676-84. DOI: 10.1038/clpt.2010.172. View